透景生命：取得杂交瘤细胞株1C2B8-2发明专利

Core Viewpoint - The company announced the issuance of a patent for a hybridoma cell line and its application, which targets Calponin1 for early screening and prognosis assessment of acute aortic dissection [1] Group 1: Patent Announcement - The company and its wholly-owned subsidiary have been granted a patent for "Hybridoma Cell Line 1C2B8-2 and Its Secreted Antibody Application" with a patent number of ZL202111082848.X, valid for 20 years [1] - The antibody developed targets Calponin1, which is significant for the early screening and prognosis evaluation of acute aortic dissection [1] Group 2: Impact on Business - The company stated that the patent will not have a significant impact on its performance at this time [1] - The issuance of the patent is expected to strengthen the company's intellectual property barriers [1]